Last reviewed · How we verify

NCT06843096: CEM_CUP_syndr

Contrast Enhanced Mammography in the Evaluation of Cancer of Unknown Primary Syndrome

ENROLLING BY INVITATION Last updated 24 February 2025
What this trial tests

trial testing Contrast-Enhanced Mammography (CEM) in Breast Cancer Diagnosis in 350 participants. Enrolling by invitation.

Timeline
1 January 2025
Primary endpoint
1 March 2025
31 January 2026

Quick facts

Lead sponsorGraziella di Grezia
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment350
Start date1 January 2025
Primary completion1 March 2025
Estimated completion31 January 2026
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Graziella di Grezia

Who can join

18 and older, female only, with Breast Cancer Diagnosis or Breast Cancer Prevention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the role of Contrast-Enhanced Mammography (CEM) in identifying the primary tumor site in patients presenting with Cancer of Unknown Primary (CUP) syndrome. By integrating functional and anatomical imaging, the study explores CEM's diagnostic value compared to standard imaging modalities in a single-center setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Contrast-Enhanced Mammography (CEM)

Trials testing the same drug.

Other recruiting trials for Breast Cancer Diagnosis

Currently open trials in the same condition.

Other Graziella di Grezia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06843096.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing